Literature DB >> 20686777

Critical analysis of mucin and signet ring cell as prognostic factors in an Asian population of 2,764 sporadic colorectal cancers.

Min-Hoe Chew1, Shen-Ann Eugene Yeo, Zhi-Peng Ng, Kiat-Hon Lim, Poh-Koon Koh, Kheng-Hong Ng, Kong-Weng Eu.   

Abstract

INTRODUCTION: Conflicting data on the clinicopathological characteristics as well as prognosis and survival of signet ring cell (SRC) and mucinous adenocarcinomas (MA) of the colorectum persist.
METHODS: Consecutive patients (2,764) with sporadic colorectal cancer from 1999 to 2005 were evaluated. The clinicopathological characteristics of these patients were reviewed. Univariate analysis was performed, and survival curves were constructed using the Kaplan-Meier method. Multivariate analysis assessed independent prognostic factors.
RESULTS: The incidence of MA and SRC is 6% and 1.1%, respectively. MA and SRC tend to occur in patients aged <or=50 years (SRC 33%, MA 22%, ordinary adenocarcinomas (OA) 14%, p = 0.001) and are more commonly right-sided (MA 30%, SRC 27%, OA 19%, p = 0.001) than OA. SRC tend to be poorly differentiated (SRC 77%, MA 26%, OA 6%, p < 0.0001) and have a higher risk of recurrence (SRC 40%, MA 26%, OA 6%, p < 0.0001). SRC and MA are more likely to have locally advanced lesions (T3/T4; SRC 100%, MA 90%, OA 83%, p = 0.002) and lymph node metastases (SRC 89%, MA 61%, OA 52%, p < 0.0001) and present with an advanced stage at diagnosis (stage III/IV SRC 94%, MA 67%, OA 56%, p < 0.0001). SRC has poorer 5-year cancer-specific survival (CSS; 11.1%, 95% confidence interval (CI) 0-22.9%) compared with MA (46.8%, 95% CI 38.6-55.0%) and OA (58.7%, 95% CI 56.5-60.9%, p < 0.001). In a multivariate analysis, SRC is an independent poor prognostic factor (HR 1.9, 95% CI 1.1-3.0) but MA is not.
CONCLUSION: SRC and MA demonstrate clinicopathologic characteristics suggestive of a different biology compared with OA. In our dataset, SRC has a significantly poorer CSS whereas survival rates for MA are similar to OA. These characteristics are similar in both Asian and Western studies reported. Asian reports however suggest a lower incidence of MA.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20686777     DOI: 10.1007/s00384-010-1033-3

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  27 in total

1.  Mucinous colorectal carcinoma.

Authors:  P H Sugarbaker
Journal:  J Surg Oncol       Date:  2001-08       Impact factor: 3.454

2.  Immunohistochemical and mutational analyses of beta-catenin, Ki-ras, and p53 in two subtypes of colorectal mucinous carcinoma.

Authors:  Satoshi Ikeda; Yosuke Shimizu; Masahiko Fujimori; Yasuyo Ishizaki; Takeshi Kurihara; Yasutomo Ojima; Masazumi Okajima; Toshimasa Asahara
Journal:  Clin Cancer Res       Date:  2003-11-15       Impact factor: 12.531

3.  A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum.

Authors:  Hakjung Kang; Jessica B O'Connell; Melinda A Maggard; Jonathan Sack; Clifford Y Ko
Journal:  Dis Colon Rectum       Date:  2005-06       Impact factor: 4.585

4.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC.

Authors:  H F Vasen; P Watson; J P Mecklin; H T Lynch
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

5.  Clinicopathological characteristics of mucinous carcinoma of the colon and rectum.

Authors:  T Nozoe; H Anai; S Nasu; K Sugimachi
Journal:  J Surg Oncol       Date:  2000-10       Impact factor: 3.454

Review 6.  Primary signet-ring cell carcinoma of the colon and rectum: report of eight cases and review of 154 Japanese cases.

Authors:  Tomoki Makino; Toshimasa Tsujinaka; Hideuki Mishima; Masakazu Ikenaga; Toshiro Sawamura; Shoji Nakamori; Kazumasa Fujitani; Motohiro Hirao; Masaki Kashiwazaki; Norikazu Masuda; Masashi Takeda; Masayuki Mano
Journal:  Hepatogastroenterology       Date:  2006 Nov-Dec

7.  Survival of patients diagnosed with either colorectal mucinous or non-mucinous adenocarcinoma: a population-based study in Canada.

Authors:  Lin Xie; Paul J Villeneuve; Amanda Shaw
Journal:  Int J Oncol       Date:  2009-04       Impact factor: 5.650

8.  Significance of signet-ring cells in patients with colorectal cancer.

Authors:  Rashmi Pande; Annette Sunga; Charles Levea; Gregory E Wilding; Wiam Bshara; Mary Reid; Marwan G Fakih
Journal:  Dis Colon Rectum       Date:  2007-11-21       Impact factor: 4.585

9.  Clinical significance of signet ring cell rectal carcinoma.

Authors:  Jinn-Shiun Chen; Pao-Shiu Hsieh; Shin-Yuan Hung; Reiping Tang; Wen-Sy Tsai; Chung-Rong Changchien; Paul-Yann Lin; Jeng-Yi Wang; Chien-Yuh Yeh
Journal:  Int J Colorectal Dis       Date:  2003-07-23       Impact factor: 2.571

10.  Incidence and survival of mucinous adenocarcinoma of the colorectum: a population-based study from an Asian country.

Authors:  Wenbo Du; James T L Mah; Jeannette Lee; Risto Sankila; Rengaswamy Sankaranarayanan; Kee-Seng Chia
Journal:  Dis Colon Rectum       Date:  2004-01-14       Impact factor: 4.585

View more
  45 in total

1.  Prognostic relevance of histopathological features in signet ring cell carcinoma of the colorectum.

Authors:  Valeria Barresi; Luca Reggiani Bonetti; Federica Domati; Luigi Baron
Journal:  Virchows Arch       Date:  2016-07-09       Impact factor: 4.064

2.  The prognostic value of signet ring cell histology in stage I/II colon cancer-a population-based, propensity score-matched analysis.

Authors:  Christoph Jakob Ackermann; Ulrich Guller; Wolfram Jochum; Bruno M Schmied; Rene Warschkow
Journal:  Int J Colorectal Dis       Date:  2018-06-07       Impact factor: 2.571

3.  Metastatic pattern in colorectal cancer is strongly influenced by histological subtype.

Authors:  N Hugen; C J H van de Velde; J H W de Wilt; I D Nagtegaal
Journal:  Ann Oncol       Date:  2014-02-06       Impact factor: 32.976

4.  Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study.

Authors:  Sare Hosseini; NamPhong Nguyen; Mohammad Mohammadianpanah; Sepideh Mirzaei; Ali Mohammad Bananzadeh
Journal:  J Gastrointest Cancer       Date:  2019-12

5.  Prognostic significance and molecular features of signet-ring cell and mucinous components in colorectal carcinoma.

Authors:  Kentaro Inamura; Mai Yamauchi; Reiko Nishihara; Sun A Kim; Curtis C Harris; Zhi Rong Qian; Shuji Ogino; Kosuke Mima; Yasutaka Sukawa; Tingting Li; Mika Yasunari; Xuehong Zhang; Kana Wu; Jeffrey A Meyerhardt; Charles S Fuchs
Journal:  Ann Surg Oncol       Date:  2014-10-18       Impact factor: 5.344

6.  Overall survival is improved in mucinous adenocarcinoma of the colon.

Authors:  J Hogan; J P Burke; G Samaha; E Condon; D Waldron; P Faul; J Calvin Coffey
Journal:  Int J Colorectal Dis       Date:  2014-01-15       Impact factor: 2.571

7.  Distinct molecular features of colorectal cancer in Ghana.

Authors:  Leon Raskin; Jonathan C B Dakubo; Nicole Palaski; Joel K Greenson; Stephen B Gruber
Journal:  Cancer Epidemiol       Date:  2013-08-17       Impact factor: 2.984

8.  Colorectal Cancer Prognosis: The Impact of Signet Ring Cell.

Authors:  Refik Bademci; Jesus Bollo; M Carmen Martinez; Maria Pilar Hernadez; Eduardo Maria Targarona
Journal:  Gastrointest Tumors       Date:  2019-07-31

9.  Parkin protein expression and its impact on survival of patients with advanced colorectal cancer.

Authors:  Claudia Caroline Veloso da Silva-Camargo; Rosimeri Kuhl Svoboda Baldin; Nayanne Louise Costacurta Polli; Amanda Pereira Agostinho; Marcia Olandosk; Lúcia de Noronha; Vanessa Santos Sotomaior
Journal:  Cancer Biol Med       Date:  2018-02       Impact factor: 4.248

10.  Clinicopathological Features and Survival of Signet-Ring Cell Carcinoma and Mucinous Adenocarcinoma of Right Colon, Left Colon, and Rectum.

Authors:  Lili Zhu; Chunrun Ling; Tao Xu; Jinglin Zhang; Yujie Zhang; Yingjie Liu; Chao Fang; Lie Yang; Wen Zhuang; Rui Wang; Jie Ping; Mojin Wang
Journal:  Pathol Oncol Res       Date:  2021-07-02       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.